Oddo BHF upgraded Novartis to Outperform from Neutral with a price target of CHF 112, up from CHF 95. The analyst says the company’s momentum isn’t fully reflected in consensus expectations.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Lexicon appoints Mike Exton as CEO, Jeff Wade as COO
- Novartis price target raised to $122.50 from $121 at Jefferies
- MorphoSys and Novartis sign delisting agreement
- Novartis announces its Phase III study of Scemblix showed ‘superior efficacy’
- Novartis says Phase III data confirm efficacy, safety of oral remibrutinib